Luong Thanh, Jang Sophie S, Said Mena, DeConde Adam S, Yan Carol H
Department of Otolaryngology - Head and Neck Surgery University of California San Diego San Diego California USA.
Laryngoscope Investig Otolaryngol. 2022 Sep 24;7(5):1299-307. doi: 10.1002/lio2.921.
Olfactory dysfunction (OD) is associated with both post-viral and inflammatory etiologies such as COVID-19 and chronic rhinosinusitis/rhinitis (CRS/R) respectively, to result in reduced quality of life (QoL). However, the former typically induces a sudden-onset OD while the latter has a gradual presentation. This study aims to establish and compare health utility values (HUVs) and olfactory-specific QoL measurements between patients with COVID-19 and CRS/R related OD.
This prospective study surveyed COVID-19 and CRS/R patients with self-reported OD using HUV assessments (EuroQol-visual analog scale [EQ-VAS], EuroQol-5 dimension [EQ-5D], time trade-off [TTO]) and olfactory and sinonasal QoL measures (questionnaire of olfactory disorders -negative and positive statements [QOD-NS + PS] and sino-nasal outcome test [SNOT-22]). A subgroup of subjects completed objective olfactory testing. Intergroup mean scores were compared using Mann-Whitney U tests.
One hundred eleven subjects were enrolled: mean age ± SD (43.0 ± 15.4 years), 55.9% female. CRS/R was associated with lower HUVs as measured by EQ-VAS (CRS/R: 0.67 ± 0.18 vs. COVID-19: 0.74 ± 0.19, = .03) and worse SNOT-22 scores in both overall (CRS/R: 49.03 ± 21.04 vs. COVID-19: 27.58 ± 18.45, < .001) and subgroup analysis of objectively confirmed OD subjects (CRS/R: 52.40 ± 22.78 vs. COVID-19: 29.84 ± 21.10, = .01). On the other hand, COVID-19 has greater burden on olfactory-specific QoL (QOD-NS + PS, COVID-19: 23.19 ± 13.73 vs. CRS/R: 17.25 ± 11.38, = .04). Both groups demonstrated a similar decrease in health using the EQ-5D assessment.
CRS/R associated OD has a more severe impact on general health and sinonasal specific QoL outcomes, while COVID-19 associated OD has a greater burden on olfactory-specific QoL.
Level 2c.
嗅觉功能障碍(OD)分别与病毒感染后和炎症性病因有关,如新型冠状病毒肺炎(COVID-19)和慢性鼻-鼻窦炎/鼻炎(CRS/R),会导致生活质量(QoL)下降。然而,前者通常导致突发性嗅觉功能障碍,而后者则表现为渐进性。本研究旨在建立并比较COVID-19和CRS/R相关嗅觉功能障碍患者的健康效用值(HUVs)和嗅觉特异性生活质量测量结果。
这项前瞻性研究使用健康效用值评估(欧洲五维度健康量表视觉模拟评分[EQ-VAS]、欧洲五维度健康量表[EQ-5D]、时间权衡法[TTO])以及嗅觉和鼻窦生活质量测量方法(嗅觉障碍问卷-阴性和阳性陈述[QOD-NS+PS]和鼻窦结局测试[SNOT-22]),对自我报告有嗅觉功能障碍的COVID-19和CRS/R患者进行了调查。一组受试者完成了客观嗅觉测试。使用曼-惠特尼U检验比较组间平均得分。
共纳入111名受试者:平均年龄±标准差(43.0±15.4岁),55.9%为女性。通过EQ-VAS测量发现,CRS/R与较低的健康效用值相关(CRS/R:0.67±0.18 vs. COVID-19:0.74±0.19,P = 0.03),并且在总体(CRS/R:49.03±21.04 vs. COVID-19:27.58±18.45,P < 0.001)和客观确诊嗅觉功能障碍受试者的亚组分析中,SNOT-22得分更差(CRS/R:52.40±22.78 vs. COVID-19:29.84±21.10,P = 0.01)。另一方面,COVID-19对嗅觉特异性生活质量的负担更大(QOD-NS+PS,COVID-19:23.19±13.73 vs. CRS/R:17.25±11.38,P = 0.04)。两组在使用EQ-5D评估时健康状况下降程度相似。
CRS/R相关的嗅觉功能障碍对总体健康和鼻窦特异性生活质量结果的影响更严重,而COVID-19相关的嗅觉功能障碍对嗅觉特异性生活质量的负担更大。
2c级。